Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

Inclusion Criteria: 1. aged 18-75 years; 2. histologically or cytologically proven diagnosis of pancreatic adenocarcinoma; 3. treatment-naive locally advanced pancreatic cancer (locally advanced status was determined by our multidisciplinary team based on the National Comprehensive Cancer Network definitions); 4. no distant metastasis as defined by CT or MRI of the chest, abdomen and pelvis; 5. at least 1 measurable lesion based on the Response Evaluation Criteria in Solid Tumors criteria (RECIST) 1.1; 6. an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; 7. adequate hematological, liver, renal function: 1. absolute neutrophil count≥1500 cell/mm3; 2. platelet count≥100×109/L; 3. hemoglobin concentration \>90 g/L; 4. albumin≥30 g/L ; 5. total bilirubin\<1.5 times the upper limit of normal; 6. alanine aminotransferase and aspartate aminotransferase≤3 times the upper limit of normal; 7. serum creatinine concentration\<1.5 times the upper limit of the normal range or less and creatinine clearance rate≥45 mL/min; 8. life expectancy of at least 3 months. Exclusion Criteria: 1. with any other malignancy within the 5 years before enrolment; 2. with active infections (bacterial, viral, or fungal) requiring systematic treatment, with hepatitis B or C infection, or a history of HIV infection, or receiving immunosuppressive therapy; 3. with peripheral sensory neuropathy at a grade \>1; 4. with a history of allergy or hypersensitivity to the study drugs; 5. pregnant or breast feeding women, reproductive aged women who refused to take adequate contraceptive measures during the study.